{
    "clinical_study": {
        "@rank": "33694", 
        "brief_summary": {
            "textblock": "RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill\n      them or deliver tumor-killing substances to them without harming normal cells.\n\n      PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who\n      have Hodgkin's lymphoma."
        }, 
        "brief_title": "Rituximab in Treating Patients With Hodgkin's Lymphoma", 
        "completion_date": {
            "#text": "August 2008", 
            "@type": "Actual"
        }, 
        "condition": [
            "Lymphoma", 
            "Hodgkin Lymphoma (Category)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the partial and complete response rates in patients with untreated or\n           recurrent/refractory lymphocyte predominant Hodgkin's lymphoma treated with rituximab.\n\n        -  Determine the efficacy of this regimen in terms of duration of disease free survival\n           and time to progression in this patient population.\n\n        -  Determine the toxicity of this regimen in these patients.\n\n      OUTLINE: Patients receive rituximab IV over several hours once a week for 4 weeks followed\n      by maintenance rituximab at 6, 12, and 18 months.\n\n      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within\n      approximately 18 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:- Patients must have lymphocyte predominant Hodgkin's disease that is\n        of B-cell lineage and expresses the CD 20 antigen.  Patients are eligible with either\n        untreated disease or refractory/relapsed disease.\n\n          -  Patients must be >= 3 years.\n\n          -  Patients must have a performance status of 0-2.\n\n          -  Patients must have an ANC > 1500/ml and a platelet count > 50,000/ml.\n\n          -  A biopsy or fine needle aspirate sample must show expression of the CD20 antigen on\n             the L adnH cells.\n\n          -  Patients must have measurable disease (at least one tumor mass measuring >1.0 cm in\n             largest dimension).\n\n          -  Patients must have no evidence of active infection.\n\n          -  Patients must read and sign IRB approved informed consent.\n\n          -  Adequate renal function as indicated by serum creatinine (Cr) < 1.5X the upper limit\n             of normal.\n\n          -  Adequate liver function as indicated by alkaline phosphatase, bilirubin, AST, and ALT\n             < 2X upper limit of normal unless related to primary disease.\n\n          -  Patients at high risk of HBV infection should be screened prior to enrollment.\n\n        Exclusion Criteria:- Concomitant or recent treatment with radiotherapy or chemotherapy.\n        Four weeks must pass from radiotherapy or cytotoxic therapy to enroll (six weeks for\n        nitrosourea compounds).\n\n          -  Major surgery, other than diagnostic surgery, within 4 weeks.\n\n          -  Female patients must be of non-childbearing potential or using adequate contraception\n             with a negative pregnancy test at study entry.\n\n          -  Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled\n             bacterial, viral, or fungal infections), or other conditions which, in the opinion of\n             the investigator and/or sponsor, would compromise other protocol objectives.\n\n          -  Treatment with an investigational drug within 30 days or 5 half-lives (of the study\n             drug with the longest half-life) prior to entry into the study, whichever is longer.\n\n          -  Evidence of other active malignancies other than cured carcinomas in situ of the\n             cervix or basal cell carcinoma of the skin.\n\n          -  Life expectancy<= 12 weeks.\n\n          -  Concurrent treatment with prednisone or other systemic steroid medication.\n\n          -  Active HBV infection or hepatitis."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003820", 
            "org_study_id": "LYMHD0003", 
            "secondary_id": [
                "75967", 
                "U2082N"
            ]
        }, 
        "intervention": {
            "description": "An initial course of rituximab at 375 mg/m2 weekly for 4 consecutive weeks.  Patients who have an objective response or stable disease to the initial course will receive additional courses of rituximab treatment every six months for 4 courses.", 
            "intervention_name": "Rituximab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 5, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford University Medical Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Trial to Evaluate the Efficacy of Anti-CD20 Antibody in Patients With Lymphocyte Predominant Hodgkin's Disease", 
        "overall_official": [
            {
                "affiliation": "Stanford University", 
                "last_name": "Ranjana Hira Advani", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Stanford University", 
                "last_name": "Richard T. Hoppe", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Progression-free survival by Kaplan-Meie", 
            "safety_issue": "No", 
            "time_frame": "15 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003820"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Stanford University", 
            "investigator_full_name": "Ranjana Advani", 
            "investigator_title": "Professor of Medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Response rates by Kaplan-Meier", 
            "safety_issue": "No", 
            "time_frame": "3, 6, 12, 18, and 24 months"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "collaborator": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Ranjana Advani", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 1999", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2012"
    }, 
    "geocoordinates": {
        "Stanford University Medical Center": "37.429 -122.169", 
        "Stanford University School of Medicine": "37.429 -122.169"
    }
}